ResMed Inc. (RMD) Q4 2026 Earnings Call Transcript

SA Transcripts 161.6K Followers Follow ResMed Inc. ( RMD ) Q4 2026 Earnings Call August 6, 2026 4:30 PM EDT Company Participants Sallilyn Schwartz - Chief Investor Relations Officer Michael Farrell - CEO & Chairman Aaron Bloomer - Chief Financial Officer Conference Call Participants Steven Wheen - Jarden Australia Pty Limited, Research Division Davinthra Thillainathan - Goldman Sachs Group, Inc., Research Division Young Li - Jefferies LLC, Research Division Dan Hurren - MST Financial Services Pty Limited, Research Division Jordan Bernstein - Stifel, Nicolaus & Company, Incorporated, Research Division Craig Wong-Pan - RBC Capital Markets, Research Division Lyanne Harrison - BofA Securities, Research Division Brett Fishbin - KeyBanc Capital Markets Inc., Research Division Laura Sutcliffe - Citigroup Inc., Research Division Brandon Vazquez - William Blair & Company L.L.C., Research Division Saul Hadassin - Barrenjoey Markets Pty Limited, Research Division Presentation Operator Hello, and welcome to the Q4 Fiscal Year 2026 ResMed Earnings Conference Call. My name is Kevin, and I'll be your operator for today's call. [Operator Instructions] Also, please note, this conference call is being recorded. Later, we'll conduct a question-and-answer session. Let me hand the call over to Salli Schwartz, ResMed's Chief Investor Relations Officer. Sallilyn Schwartz Chief Investor Relations Officer Thanks, Kevin. I want to welcome our listeners to ResMed's Fourth Quarter Fiscal Year 2026 Earnings Call. We are live webcasting this call, and the replay will be available on the Investor Relations section of our corporate website later today. Our earnings presentation is available online now. Please note, we will be displaying our earnings presentation during our prepared remarks, and then we'll post the slides to our IR website after the conclusion of our remarks. During today's call, we will discuss several non-GAAP measures that we believe provide useful information for investors. This information is not intended to be considered in isolation or as a substitute for GAAP financial information. We encourage you to review the